Embera is developing the first medication that treats addiction by moderating activity in the stress response system.

EMB-001 may potentially reduce the cravings and loss of control that drive addiction by uniquely targeting multiple pathways, to maximize potential efficacy more than either drug used alone. A therapy that breaks these barriers and results in long term abstinence and recovery would be a significant contribution to the treatment of a broad range of addictions.

Media & Publications

,

Embera NeuroTherapeutics Receives $11M Grant from National Institute on Drug Abuse for the Clinical Development of EMB-001 for the treatment of Cocaine Addiction

/
Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for cocaine, nicotine, and other addictions, today announced that it has received an $11.1 million, three-year grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH). The grant will support continued clinical development of EMB-001 for the treatment of cocaine addiction, which is clinically termed “cocaine use disorder.”
,

Embera CEO Provides Update on Addiction Treatment

/
Robert Linke, president and CEO of Embera Neurotherapeutics, a specialized biopharmaceutical firm based in Shreveport, Louisiana spoke with Drug Discovery & Development via email about his company's progress on the development of drugs that battle addiction.
,

Embera NeuroTherapeutics Announces Successful Completion of Phase 1 Clinical Trial Testing EMB-001, a Potential Novel Treatment for Addictions

/
Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for cocaine use disorder, smoking cessation, and other addictions, today announced that EMB-001 met the primary endpoints of safety and tolerability in a Phase 1 clinical trial. Embera also announced that the Company’s Chief Executive Officer, Robert Linke and Chief Medical Officer, Dr. Michael Detke, will present at the Biotech Showcase on Monday, January 11, 2016 at 2:30pm in San Francisco, California.